Thanks to Plabs for the interim dividend. Did not expect it :) On top of the dividend, shareholders would have noticed two more major activities in the report under notes A10 pg 8 - additions of industrial land and construction of 1 block of factory :)

Perhaps Mr. Bu is eyeing the expansion plan for its manufacturing and trading business. Extracted these from the latest annual report - In December 2023, Osmosis has commenced construction an additional one block factory to cater for Osmofat production in Nilai. And recent land acquisition is to facilitate a seamless expansion of its trading business in the near future.

That's a good question and a tough one, T&S. Nothing mentioned about it. However, if you have been following the manufacturing segment, you will noticed that FY2023 revenue at 5.4M is the highest by far that I can recalled; at least over the last 5 years. Used to be hovering around plus minus 3M to less than 5M; FY2022 was at 2.8M. Additionally, you will also noticed that there are new markets added as part of risk mitigation for epidemics over the last two years - China, Egypt, and Belarus. Barring any unforeseen circumstances, the manufacturing segment should be seeing growth again - new markets and available capacity :)